What is DBV Technologies?
Founded in 2002 and maintaining dual headquarters in Montrouge, France, and New York, New York, DBV Technologies operates at the intersection of scientific research and commercial medical application. The company is dedicated to the development of innovative treatments, positioning itself as a key player in the B2B biopharmaceutical space. Its market position is defined by a commitment to rigorous clinical research and the advancement of specialized health technologies that address unmet medical needs. By maintaining a presence in both European and North American markets, the firm effectively bridges the gap between foundational scientific discovery and enterprise-level healthcare solutions.
How much funding has DBV Technologies raised?
DBV Technologies has raised a total of $808.3M across 9 funding rounds:
Series B
$6.6M
Series C
$25.5M
Stock Offering
$44.5M
Share Placement
$33.9M
Stock Offering
$153.7M
Share Placement
$194M
Other Financing Round
$306.9M
Stock/Share Issuance
$30M
Series B (2009): $6.6M led by Sofinnova Partners and ALK-Abello
Series C (2011): $25.5M supported by Shire Pharmaceuticals, Sofinnova Partners, Lundbeckfonden Ventures, ALK Abello, InnoBio Fund, and Alto Invest
Stock Issuance/Offering (2012): $44.5M, investors not publicly disclosed
Share Placement (2013): $33.9M backed by Apax Partners, Altamir, Innobio, ALK Abello, and Lundbeckfond
Stock Issuance/Offering (2020): $153.7M, investors not publicly disclosed
Share Placement (2022): $194M, investors not publicly disclosed
Other Financing Round (2025): $306.9M supported by Surveyor Capital, Octagon Capital Group, Adage Capital Management, Vivo Capital, Yiheng Capital, Bpifrance, MPM BioImpact, and Janus Henderson Investors
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Key Investors in DBV Technologies
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Apax Partners
A global private equity advisory firm that focuses on supporting the growth of businesses in the technology, services, and consumer sectors.
Lundbeckfonden Ventures
A commercial research foundation that awards grants and manages an international portfolio of venture capital companies within the biomedical and brain research fields.
What's next for DBV Technologies?
With the recent influx of capital, DBV Technologies is poised to enter a critical phase of operational scaling and product development. The strategic deployment of these funds will likely focus on advancing its core clinical programs and strengthening its competitive advantage in the biopharmaceutical market. As the company moves forward, the focus will remain on achieving key regulatory milestones and optimizing its research infrastructure to ensure long-term value creation. The continued support from sophisticated institutional investors suggests a clear path toward commercialization and sustained growth in the evolving global health landscape.
See full DBV Technologies company page
